MIE-101

N/A

Report date: 2025/01/26 17:18:04

Base Information

Drug NameMIE-101
Drug Alias NameCPMV Nanoparticle-Based Immunotherapy (Mosaic ImmunoEngineering)TLR Tri-Agonist (Mosaic ImmunoEngineering)TLR tri-agonist (Mosaic ImmunoEngineering)MIE-101
ClassificationBiologics
Mechanisms of ActionToll like receptor 2 agonistsToll like receptor 4 agonistsToll like receptor 7 agonists
TargetsToll like receptor 4Toll like receptor 2Toll like receptor 7
Therapy Area/IndicationsSolid tumoursBrain NeoplasmsOvarian Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMosaic ImmunoEngineering Inc
China Registration ClassN/A

Develop Information

Active CompaniesMosaic ImmunoEngineering Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursBrain NeoplasmsOvarian Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A